Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v25.i1.10
pages 1-61

Engineered Nanocarriers of Doxorubicin: A Current Update

Rajesh R. Patil
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University of Mumbai, N.P.Marg, Mumbai 400 019, India
Swati A. Guhagarkar
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University of Mumbai, N.P.Marg, Mumbai 400 019, India
Padma V. Devarajan
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University of Mumbai, N.P.Marg, Mumbai 400 019, India

SINOPSIS

Doxorubicin remains the first line of treatment for various cancers ever since its discovery in 1971. Cardiotoxicity and nephrotoxicity associated with unformulated doxorubicin triggered the development of doxorubicin nanocarriers. Although the therapeutic profile of doxorubicin is appreciably improved by entrapping in nanocarriers, they are largely taken up by organs of the reticuloendothelial system. Engineered nanocarriers of doxorubicin refer to carriers modified to escape recognition by reticuloendothelial system and/or functionalized with target specific ligands for selective accumulation at the target site. The first developments in engineered nanocarriers were the stealth carriers. These effectively bypassed the reticuloendothelial system and enhanced the therapeutic profile of doxorubicin by enabling passive accumulation in tumors. Stealth nanocarriers of doxorubicin revealed significant decrease in cardiotoxicity and nephrotoxicity, which led to the approval of liposomal doxorubicin for clinical applications. Success of liposomal doxorubicin was soon dulled by the appearance of newer toxicities like palmar-plantar erythrodysesthesia commonly referred as hand foot syndrome. The search for the “magic bullet” of doxorubicin has further intensified and resulted in design of engineered nanocarriers with high specificity for cancer cells. This review charts the progress from nanocarriers to engineered nanocarriers of doxorubicin, and highlights the current status of engineered nanocarriers of doxorubicin in clinical trials.


Articles with similar content:

Engineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 1
Amit K. Jain, Manasmita Das, Nitin K. Swarnakar, Sanyog Jain
Cracking the Junction: Update on the Progress of Gastrointestinal Absorption Enhancement in the Delivery of Poorly Absorbed Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 2
David J. Brayden, Siobhan McClean, Sam Maher, Linda Feighery
Ligand-Appended BBB-Targeted Nanocarriers (LABTNs)
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 2
Ankit Jain, Sanjay Kumar Jain
Functional Polymeric Nanoparticles: An Efficient and Promising Tool for Active Delivery of Bioactives
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.23, 2006, issue 4
Senthilkumar Murugesan, Tathagata Dutta, Abhay Asthana, Manoj Tare, Surbhi Saraf, Narendra Kumar Jain, Vijayaraj Rajkumar, Manoj Nahar, Dinesh Mishra
Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 6
Sanaul Mustafa, Roopa S Pai, Gurinder Singh